Sobetirome is primarily investigated for its potential therapeutic applications in treating thyroid hormone-related disorders. It acts as a selective thyroid hormone receptor beta agonist, making it particularly useful in targeting conditions like hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD). By mimicking the effects of thyroid hormones, it helps regulate lipid metabolism, reducing cholesterol levels and improving liver health. Additionally, research explores its role in neurodegenerative diseases, such as Alzheimer's, due to its ability to enhance brain function and reduce amyloid plaques. Its selectivity minimizes side effects often associated with broader thyroid hormone activation, making it a promising candidate for targeted therapies.